KAHR Medical
Fusion Proteins for Treating Cancer and Autoimmune Diseases
Company Overview
Snapshot
Founded in September 2005, KAHR Medical operates with 11–50 employees. The company has raised $118.27 million across 12 funding rounds from 17 investors. In January 2026, KAHR Bio announced strong topline Phase 2 results for its lead candidate, DSP107, in combination with anti-PD-L1 therapy for colorectal cancer.
Business overview
KAHR Medical is a clinical-stage biotechnology company focused on developing immuno-oncology drug candidates for treating various cancers. Its core technology is based on multifunctional immuno-recruitment proteins (MIRP) that selectively target and bind to tumors by utilizing the overexpression of checkpoint antigens on cancer cells. These MIRPs bridge cancer cells to immune cells, combining immune checkpoint inhibition with localized immune cell activation to unmask cancer cell camouflage and recruit the adaptive immune system to kill cancer cells. The company's lead product, DSP107, is a CD47x41BB targeting compound designed to simultaneously target cancer cells, weaken their defenses, and activate both innate and adaptive immune responses. KAHR Medical operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving markets in the United States and Europe.
Strategic signal
In January 2026, KAHR Bio announced strong topline Phase 2 results for DSP107 in combination with anti-PD-L1 therapy for colorectal cancer. This positive clinical trial outcome is a significant validation of KAHR's MIRP technology platform, indicating potential efficacy in a challenging cancer type and signaling strong progress towards commercialization and further clinical development for investors.
Log in to access full profile ›Company Intelligence Q&A
- What were the recent clinical trial results for DSP107?
- In January 2026, KAHR Bio announced strong topline Phase 2 results for DSP107 in combination with anti-PD-L1 therapy in patients with colorectal cancer.
- What was the outcome of the Phase I trial for DSP107 in combination with anti-PD-L1?
- In May 2023, KAHR reported dose escalation results from its Phase I trial of DSP107 in combination with anti-PD-L1 in patients with advanced solid tumors.
- When did KAHR Medical receive FDA clearance for clinical trials?
- In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
- What strategic partnership did KAHR Medical form in June 2021?
- In June 2021, Samsung Biologics and KAHR Medical announced a development and manufacturing agreement for KAHR's cancer immunotherapy drug candidate.